CN106074206A - 一种护肤主剂、制备方法及其应用 - Google Patents
一种护肤主剂、制备方法及其应用 Download PDFInfo
- Publication number
- CN106074206A CN106074206A CN201610517463.4A CN201610517463A CN106074206A CN 106074206 A CN106074206 A CN 106074206A CN 201610517463 A CN201610517463 A CN 201610517463A CN 106074206 A CN106074206 A CN 106074206A
- Authority
- CN
- China
- Prior art keywords
- skin
- skin protection
- protection host
- vitamin
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 206010000496 acne Diseases 0.000 claims abstract description 47
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 21
- 230000002087 whitening effect Effects 0.000 claims abstract description 18
- 208000003351 Melanosis Diseases 0.000 claims abstract description 15
- 206010008570 Chloasma Diseases 0.000 claims abstract description 9
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 7
- 201000004700 rosacea Diseases 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 62
- 239000000284 extract Substances 0.000 claims description 44
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 36
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 34
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000194 fatty acid Substances 0.000 claims description 21
- 235000011187 glycerol Nutrition 0.000 claims description 21
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 21
- 235000019136 lipoic acid Nutrition 0.000 claims description 18
- 229960002663 thioctic acid Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 17
- 229960000304 folic acid Drugs 0.000 claims description 17
- 235000019152 folic acid Nutrition 0.000 claims description 17
- 239000011724 folic acid Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000008158 vegetable oil Substances 0.000 claims description 17
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 16
- 241001116389 Aloe Species 0.000 claims description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 16
- 229930003268 Vitamin C Natural products 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
- 235000011399 aloe vera Nutrition 0.000 claims description 16
- 239000000787 lecithin Substances 0.000 claims description 16
- 235000010445 lecithin Nutrition 0.000 claims description 16
- 229940067606 lecithin Drugs 0.000 claims description 16
- 235000019154 vitamin C Nutrition 0.000 claims description 16
- 239000011718 vitamin C Substances 0.000 claims description 16
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 claims description 15
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 15
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 claims description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 15
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 15
- 229940114124 ferulic acid Drugs 0.000 claims description 15
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 15
- 235000001785 ferulic acid Nutrition 0.000 claims description 15
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 15
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 15
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 15
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 14
- 239000011716 vitamin B2 Substances 0.000 claims description 14
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000011726 vitamin B6 Substances 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 230000001815 facial effect Effects 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 9
- 235000003969 glutathione Nutrition 0.000 claims description 9
- 229960003180 glutathione Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 8
- 229960001763 zinc sulfate Drugs 0.000 claims description 8
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 8
- 238000010009 beating Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000005453 pelletization Methods 0.000 claims description 4
- 235000004347 Perilla Nutrition 0.000 claims description 3
- 244000124853 Perilla frutescens Species 0.000 claims description 3
- 240000005481 Salvia hispanica Species 0.000 claims description 3
- 235000001498 Salvia hispanica Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 127
- 150000003254 radicals Chemical class 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 6
- 230000008929 regeneration Effects 0.000 abstract description 5
- 238000011069 regeneration method Methods 0.000 abstract description 5
- 230000001629 suppression Effects 0.000 abstract description 5
- 210000002752 melanocyte Anatomy 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 230000001741 anti-phlogistic effect Effects 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000005808 skin problem Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 46
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 26
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 229930003427 Vitamin E Natural products 0.000 description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 13
- 235000019165 vitamin E Nutrition 0.000 description 13
- 229940046009 vitamin E Drugs 0.000 description 13
- 239000011709 vitamin E Substances 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- VRSMJNVXOITYPE-FSDIUQKZSA-N ethyl 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VRSMJNVXOITYPE-FSDIUQKZSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940040145 liniment Drugs 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 244000007703 Mentha citrata Species 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- 235000008660 Mentha x piperita subsp citrata Nutrition 0.000 description 1
- 101100330292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-12 gene Proteins 0.000 description 1
- 101100426732 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-9 gene Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000404144 Pieris melete Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- JLQNHALFVCURHW-UHFFFAOYSA-N cyclooctasulfur Chemical compound S1SSSSSSS1 JLQNHALFVCURHW-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000003087 glucogenic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于护肤品领域,提供了一种护肤主剂、制备方法和应用。所述护肤主剂可以广泛用于美白肌肤,防治青春痘(痤疮、粉刺、黑头、酒糟鼻等)、色斑(雀斑、黄褐斑、老年斑等)和修复创伤色痕。所述护肤主剂由一系列具有杀菌消炎、消灭自由基、提高免疫力、促进细胞再生以及抑制黑色素细胞活性功能的组分制成,因此,该护肤主剂能够高效渗透皮肤,直达粉刺和色斑部位最里层,对于各类皮肤问题具有快速的治疗效果。同时,本发明还可制备为多种剂型广泛应用于美白护肤领域。
Description
技术领域
本发明涉及护肤品领域,特别涉及一种护肤主剂、制备方法及其应用。
背景技术
当下,人们生活水平提高,皮肤美白已成时尚,防治青春痘、色斑、创伤色痕、美白肌肤的专利技术和产品应运而生,层出不穷,然而现有药物用途单一,使用的药物种类多而繁杂,价格不菲,而且效果也很不尽人意,致使许多人为此苦恼。因此,生产一种能快速而有效治疗青春痘、色斑和修复创伤色痕的美白肌肤的护肤药剂刻不容缓。
目前市面上有各种各样治疗青春痘、色斑和创伤色痕的护肤品,但是大部分功能华而不实,外用捈抹的只能清洁到皮肤表面,难以清洁到毛孔内部肌肤,导致深层肌肤堆积废物,内服的难以清除自由基等体内形成青春痘和色斑的根源,所以疗效难以实现。现有技术中,既可外敷又可内服的药剂尚属少见,特别是既可用于快速治疗青春痘又可用于快速治疗色斑,同时又可用于美白肌肤的更是少见。
有鉴于此,特提出本发明。
发明内容
本发明的第一目的在于提供一种护肤主剂,它可以广泛用于美白肌肤,还可以防治青春痘、色斑、修复创伤色痕,与现有技术中的护肤主剂相比具有适用广泛,疗效快速确切的优点。
本发明的第二目的在于提供一种所述护肤主剂的制备方法,本发明方法,通过将本发明中各组分混合以制备本发明护肤主剂,该方法具有制备简单、操作便捷等优点。本护肤主剂不仅可以直接用于护肤治疗,还可以根据需要加入一些水、甘油和富含ω-3脂肪酸的植物油以及不同剂量的果蔬汁或果蔬浆等成分,制成霜剂和乳液剂等供外用,还可以制成片剂或胶囊剂供内服。
本发明的第三目的在于提供本发明护肤主剂在制备美白护肤药物中的应用。本发明护肤主剂通过将安全有效,同时见效快的组分作为原料,能高效渗透皮肤,直达粉刺和色斑部位最里层、消灭自由基,因而本发明护肤主剂能够有效的用于防治青春痘、色斑、修复创伤色痕等皮肤问题,而且起效迅速,疗效稳定。
为了实现本发明的上述目的,特采用以下技术方案:
所述护肤主剂,按照重量百分数计,其主要由以下组分制成:α-硫辛酸7%~40%、还原型谷胱甘肽4%~22%、L-半胱氨酸7%~26%、薰衣草提取物3%~6%、丹参提取物5%~16%、黄岑提取物7%~15%、芦荟粉0%~3%、根皮素0%~2%、阿魏酸0%~2%、卵磷脂0.4%~1%、维生素C 6%~12%、维生素E 2%~7%、维生素B2 2%~6%、维生素B60.4%~2%、硫酸锌0%~2.5%和叶酸0.05%~1%。
本发明中各组分的功效为:
α-硫辛酸被称为“万能抗氧化剂”,更是自由基捕手,还能保存和再生其它抗氧化剂如维生素C和维生素E,修复肝细胞、改善胰岛功能与葡萄糖代谢、螯合重金属、提高人体增肌减脂的能力,对于黑眼圈、皱纹及斑点等效能卓著。再加上α-硫辛酸具有的强化代谢功能会让身体的血液循环变好,使肌肤的黯沉改善、毛细孔变小。同时,α-硫辛酸具有降低皮肤细纹,形成及保护皮肤细胞不受紫外线侵害,预防皮肤老化的功能。而且,由于α-硫辛酸比维他命E的分子还要小,并兼具水溶性和脂溶性,所以能够高效渗透皮肤。
本发明中,所述α-硫辛酸典型但非限制性的含量为:7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%、22、23%、24%、25%、26%、27%、28%、29%、30%、31%、32%、33%、34%、35%、36%、37%、38%、39%或40%。
还原型谷胱甘肽是一种强效的抗氧化成分,被称为自由基清除剂,具有广谱解毒和保肝的作用。并且,还原型谷胱甘肽还具有抗痘作用,能恢复已被破坏的酶分子中-SH基的活性功能,使酶重新恢复活性。同时,还原型谷胱甘肽可由内而外双重锁定酪氨酸酶,阻止酪氨酸酶和酪氨酸的渗透,以此达到抑制黑色素形成的目的。还原型谷胱甘肽对祛除皱纹、增加肌肤弹性,收缩毛孔、淡化色素,全身美白有极好的功效。
本发明中,所述还原型谷胱甘肽典型但非限制性的含量为:4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%或22%。
L-半胱氨酸是人体的必需氨基酸和生糖氨基酸,其对广泛的毒物具有有效的解毒作用,能有效地预防和治疗放射性伤害。并且,L-半胱氨酸在皮肤蛋白的角蛋白生成中维持重要的琉基酶的活性,可以补充硫基,以维持皮肤的正常代谢,防皮肤衰老,同时调节表皮最下层的色素细胞生成的底层黑色素,除去皮肤本身的黑色素,是种非常理想的除痘除斑的自然美白化妆品。每当皮肤出现炎症、过敏使胆磷醋酶等的琉基酶降低时,补给L-半胱氨酸可维持琉基酶的活性,可以改善炎症和过敏的皮肤症状。同时,L-半胱氨酸具有溶解角质的作用,所以对角质肥厚的皮肤病也有疗效。
本发明中,所述L-半胱氨酸典型但非限制性的含量为:7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%、22%、23%、24%、25%或26%。
薰衣草提取物可以促进细胞再生,平衡油脂分泌,清洁皮肤,消毒抗菌,避免感染。薰衣草提取物还可以促进青春痘和小伤口迅速愈合,防止留下疤痕,并能保湿、抑油、收敛毛孔,预防痘痘发生。
本发明中,所述薰衣草提取物典型但非限制性的含量为:3%、4%、5%或6%。
丹参提取物具有活血化瘀,促进创面愈合的功效,是治疗粉刺棒状杆菌的主要中药,即通过抗菌消炎起治疗粉刺作用。丹参有良好的透皮吸收效果,能够有效抑制皮肤脂质氧化,改善局部微循环,被毛孔吸收之后,能够刺激皮下的血液循环,减轻内皮损伤、促进内皮修复。丹参提取物还可以抑制脂质氧化反应,调节水油平衡,消除由于血液循环不畅而导致的痤疮、暗疮、色斑。
本发明中,所述丹参提取物典型但非限制性的含量为:5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%或16%。
黄岑提取物对金色葡萄球菌等细菌、真菌具抑制作用,同时具抗炎活性。黄岑提取物可阻止过敏介质释放,具抗过敏性。同时,它还具有清热解毒,凉血散瘀,抗氧化,消除自由基,抗紫外线,抗幅射和抑制酪氨酸酶的作用,具有使色素沉着黄褐斑消失的功能。
本发明中,所述黄岑提取物典型但非限制性的含量为:7%、8%、9%、10%、11%、12%、13%、14%或15%。
芦荟粉具有使皮肤收敛、柔软、保湿、消炎、漂白的性能。芦荟粉中含有的水解蛋白酶有解除硬化、角化、改善伤痕的作用,芦荟粉对粉刺、雀斑、痤疮以及烫伤、刀伤、虫咬等亦有很好的疗效。同时芦荟粉还具有分解体内有害物质,解除消炎剂、抗组胺药剂引起的副作用,并可以改善放射线辐射引起的白细胞减少症,对大部分过敏症状都有效果。
本发明中,所述芦荟粉典型但非限制性的含量为:0%、1%、2%或3%。
根皮素有极强的抗氧化性,可清除皮肤内的自由基,能阻止糖类成分进入表皮细胞,从而抑制皮腺的过度分泌,治疗分泌旺盛性粉刺等。根皮素对于酪氨酸酶有良好的抑制作用,具有抑制黑色素细胞活性,对各种皮肤色斑有淡化作用。根皮素是一种非常安全有效的祛斑美白剂。根皮素具有非常好的保湿作用,能吸收本身重量的4~5倍水分。同时,根皮素还是非常安全有效的透皮促渗剂,能促进配方中其他功能因子的吸收利用,使其发挥出更好的功效。
本发明中,所述根皮素典型但非限制性的含量为:0%、1%或2%。
阿魏酸具有抗炎止痛,抗血小板聚集,清除自由基和良好的抗氧化作用。阿魏酸能够抑制或降低黑色素细胞的增殖活性,抑制酪氨酸酶的活性。此外,阿魏酸具有防晒抗幅射能力,能够有效地吸收紫外线,预防或减少紫外线对皮肤的损伤。
本发明中,所述阿魏酸典型但非限制性的含量为:0%、1%或2%。
卵磷脂是天然解毒剂,具有抗氧化、渗透、保湿和乳化等作用,卵磷脂可以保护生物膜免受人体代谢过程中的自由基损伤,改善皮肤的营养,促进皮肤细胞的再生,增加修补被损的细胞膜,增加脂肪酸的不饱和度,有利于延缓细胞的衰老。卵磷脂还可改善皮肤之触感,降低油腻性,在皮肤上形成一薄膜,对皮肤内部的浸透性好、贮留性高,另外卵磷脂与水溶性和油溶性物质都能互相包容。
本发明中,所述卵磷脂典型但非限制性的含量为:0.4%、0.5%、0.6%、0.7%、0.8%、0.9%或1%。
维生素C能促进胶原蛋白合成,并且具有分解皮肤中黑色素、预防色素沉着,防治色斑发生的作用,并有促进伤口愈合、强健血管和骨骼的功效。同时维生素C还可增强中性粒细胞的趋化性和变形能力,提高杀菌能力
本发明中,所述维生素C典型但非限制性的含量为:6%、7%、8%、9%、10%、11%或12%。
维生素E能够抗氧化抗自由基,可以加强体内的免疫反应。维生素E还可从器官组织内清理废物,防止血液中的过氧化脂质增多,防止血小版过度凝集,减少老人斑的沉积。
本发明中,所述维生素E典型但非限制性的含量为:2%、3%、4%、5%、6%或7%。
维生素B2可以参与机体内各种代谢,促进生长发育,加速细胞再生,维持皮肤生长。
本发明中,所述维生素B2典型但非限制性的含量为:2%、3%、4%、5%或6%。
维生素B6是制造抗体和红血球的必要物质,可帮助色氨酸转换成烟酸(维生素B3),同时维生素B6还可以防止各种神经、皮肤类疾病。
本发明中,所述维生素B2典型但非限制性的含量为:0.4%、0.5%、0.6%、0.7%、0.8%、0.9%、1%、1.1%、1.2%、1.3%、1.4%、1.5%、1.6%、1.7%、1.8%、1.9%或2%。
硫酸锌具有促进伤口和创伤的愈合的功效,对于青春痘、疤痕的修复均具有一定的效果。
本发明中,所述硫酸锌典型但非限制性的含量为:0%、1%、1.5%、2%、2.5%。
叶酸能促进人体对维生素A的利用。同时,叶酸还可与维生素C起协同作用,保护皮肤的健康,减少皮肤发生感染。叶酸对皮肤中的胶原纤维和弹力纤维有“滋润”作用,从而改善和维护皮肤的弹性。同时叶酸能促进皮肤内的血液循环,使皮肤得到充分的营养与水分,以维持皮肤的柔嫩与光泽,叶酸还可抑制色素斑、老年斑的形成,减少面部皱纹及洁白皮肤,防治痤疮。
本发明中,所述叶酸典型但非限制性的含量为:0.05%、0.1%、0.2%、0.3%、0.4%、0.5%、0.6%、0.7%、0.8%、0.9%或1%。
本发明通过上述成分进行充分混合后制成的护肤主剂,可以广泛用于美白肌肤,还可以防治青春痘(痤疮、粉刺、黑头、酒糟鼻等)、色斑(雀斑、黄褐斑、日照斑、幅射斑、妊娠斑、老年斑等)以及修复创伤疤痕。上述护肤主剂中的各组分不但能够各自发挥原来的功效,同时各组分间能够起到协同作用,进一步加强其疗效,对于皮肤的美白护理优于现有护肤品的作用。
可选的,本发明中,所述薰衣草提取物为10:1或20:1的薰衣草提取物;优选的,本发明中,所述薰衣草提取物为10:1的薰衣草提取物。
可选的,本发明中,所述丹参提取物为10:1或20:1的丹参提取物;优选的,本发明中,所述丹参提取物为10:1的丹参提取物。
可选的,本发明中,所述黄苓提取物为10:1或20:1的黄苓提取物;优选的,本发明中,所述黄苓提取物为10:1的黄苓提取物。
可选的,本发明中,所述薰衣草提取物、丹参提取物、黄苓提取物和芦荟粉由西安普莱特生物工程有限公司提供;
所述α-硫辛酸由上海陆安生物科技有限公司提供;
所述L-半胱氨酸由北京精华***医药科技有限公司提供;
所述根皮素由成都瑞芬思生物科技有限公司提供;
所述阿魏酸由广州柏腾化工有限公司提供;
所述卵磷脂由郑州荔诺生物科技有限公司提供,
本发明中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
进一步地,按照重量百分数计,所述护肤主剂主要由以下组分制成:α-硫辛酸6%~30%、还原型谷胱甘肽6%~20%、L-半胱氨酸10%~20%、薰衣草提取物4%~5%、丹参提取物6%~15%、黄岑提取物8%~10%、芦荟粉1%~2%、根皮素1%~1.5%、阿魏酸1%~1.5%、卵磷脂0.6%~0.8%、维生素C8%~10%、维生素E3%~5%、维生素B23%~5%、维生素B60.6%~1.5%、硫酸锌0.5%~2%和叶酸0.06%~0.8%。
本发明中,通过对各组分原料用量比例的进一步调整和优化,从而进一步优化了本发明护肤主剂的药效。
本发明还提供了一种护肤主剂的制备方法,所述方法包括如下步骤:将上述护肤主剂中任一项所述组分混合后,即得所述护肤主剂。
本发明中,通过将本发明组合物混合以制备护肤主剂的方法,具有制备方法简单,所制备的药物使用方便、疗效好等优点。
进一步地,所述护肤主剂可制成为片剂、胶囊剂、乳液剂或霜剂中的一种。
进一步地,所述方法还进一步包括,将上述护肤主剂中任一项所述组分混合后,取100重量份组合物,加入甘油1~2重量份、富含ω-3脂肪酸的植物油1~5重量份,羧甲基纤维素钠0.2~0.5重量份和硬脂酸镁0.3~1.5重量份充分混合,随后进行制粒压片或灌装胶囊等制作,制得片剂或胶囊剂。
所述制粒压片或灌装胶囊等过程与现有技术相同。
本发明中,通过将本发明组合物制备成为片剂或胶囊剂,从而进一步方便了护肤主剂的应用。
进一步地,所述方法还进一步包括,将上述护肤主剂中任一项所述组分混合后,取100重量份组合物,加甘油20~100重量份,加无菌水或果蔬汁200~600重量份,加入富含ω-3脂肪酸的植物油0~10重量份,羧甲基纤维素钠0.2~0.5重量份,加入香精1~3份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂,随后还可浸泡纸膜,制得护肤面膜。
本发明中,通过将本发明组合物与甘油水溶液等具有良好渗透性,并可以增强细胞中超氧化物歧化酶活性并抑制过敏性发生的的基质混合,从而进一步提高了本发明护肤主剂的渗透性以及抗菌性能,并使得本发明护肤主剂见效更快,同时还能够进一步改善皮脂腺代谢,改善内分泌失调。
进一步地,所述方法还包括将上述护肤主剂中任一项所述组分混合后,取100重量份组合物,加甘油30~50份,加无菌水或果蔬汁20~60份,加入富含ω-3脂肪酸的植物油20~40重量份,羧甲基纤维素钠0.2~0.5重量份,加热至75~80℃搅打或以乳化机乳化成膏状,加入香精1~3份,制得霜剂。
本发明中,含丰富的ω-3脂肪酸的植物油是指奇亚子油、紫苏油、月见草油、胡麻子油的一种或几种的混合物。富含ω-3脂肪酸的植物油可明显提高红细胞中超氧化物歧化酶的活力,抑制过敏性反应,清除自由基,对于肌肤细胞有保护及重建的功效。
ω-3脂肪酸能渗透至细胞,强化其紧密度,使肌肤恢复弹性与光泽,因此具有抗老防皱,延缓衰老的作用。ω-3脂肪酸还可以调节皮脂腺的代谢,改善皮肤失调现象,从而治疗调节内分泌引起的青春豆和黑斑,达到健美皮肤的功效。
进一步的,本发明还提供了本发明护肤主剂在制备美白护肤药物中的应用。
本发明通过将具有杀菌消炎、提高免疫力以及促进细胞再生功效的组分作为原料并配合使用,从而使得本发明护肤主剂具有良好的药效以及渗透性,并能够广泛应用于美白护肤领域。
进一步地,本发明提供的护肤主剂所述功能为美白护肤,所述美白护肤还是指防治青春痘、色斑和修复创伤色痕,其中,所述青春痘包括痤疮、粉刺、黑头和酒糟鼻等;所述色斑包括雀斑、黄褐斑和老年斑等。
与现有技术相比,本发明的有益效果为:
(1)本发明护肤主剂可以广泛用于美白肌肤,还可以防治青春痘(痤疮、粉刺、黑头、酒糟鼻等)、色斑(雀斑、黄褐斑、日照斑、幅射斑、妊娠斑、老年斑等)以及修复创伤色痕。
(2)本发明护肤主剂使用了保湿剂、活血化瘀剂、抗氧化剂、自由基清除剂、抗炎解毒剂、抗紫外线、抗幅射防紫外线剂、黑色素细胞活性酪氨酸酶和酪氨酸抑制剂,通过上述配比该护肤主剂的有效成分可以直达粉刺和色斑部位最里层、消灭自由基,破坏粉刺色斑DNA和蛋白合成,防止皮脂腺管过度角化以及皮脂分泌增加所导致的皮脂腺管与毛孔堵塞等症状,从而达到防治青春痘、色斑、修复创伤色痕、美白肌肤的快速疗效。
(3)本发明护肤主剂通过添加α-硫辛酸等具有良好渗透性的高效的小分子原料,也使得本发明护肤主剂具有良好的渗透性,能够快速见效。
(4)本发明护肤主剂中各组分安全健康,且组分间能够起到协同作用,因而使得本发明护肤主剂具有很好的疗效。同时,本发明护肤主剂价格便宜,使用方便,具有很好的市场前景。
(5)本发明护肤主剂能够直接用于肌肤护理治疗,也可进一步根据需要加入不同剂量的无菌水或果蔬汁,以及甘油和奇亚子油、紫苏油、月见草油、胡麻子油、羧甲基纤维素钠等,分别制成霜剂、乳液剂等供外用,同时本发明护肤主剂,还可以制成片剂或胶囊剂供内服,以达到内外兼治的目的。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
实施例1
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸7%、还原型谷胱甘肽4%、L-半胱氨酸24%、薰衣草提取物6%、丹参提取物16%、黄岑提取物15%、芦荟粉3%、根皮素2%、阿魏酸2%、卵磷脂0.4%、维生素C 9.2%、维生素E 2%、维生素B2 6%、维生素B60.4%、硫酸锌2%和叶酸1%。
随后,取100重量份上述护肤主剂,加入甘油2重量份、富含ω-3脂肪酸的植物油5重量份、羧甲基纤维素钠0.5重量份和硬脂酸镁1.5重量份充分混合,然后进行制粒压片制作,制得片剂。
或取100重量份上述护肤主剂,加入甘油2重量份、含丰富的ω-3脂肪酸的植物油5重量份、羧甲基纤维素钠0.5重量份和硬脂酸镁1.5重量份充分混合,然后进行灌装胶囊的制作,制得胶囊剂。
实施例2
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸40%、还原型谷胱甘肽6%、L-半胱氨酸7%、薰衣草提取物6%、丹参提取物6%、黄岑提取物9%、根皮素1%、阿魏酸1%、卵磷脂1%、维生素C7%、维生素E7%、维生素B2 3.6%、维生素B62%、硫酸锌2.4%和叶酸1%。
随后,取100重量份组合物,加甘油50重量份,加无菌水或果蔬汁600重量份,羧甲基纤维素钠0.2重量份,加入香精1份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂,随后浸泡纸膜,制得护肤面膜。
效果例1
90名志愿者,均选自经医院诊断为青春痘的患者,其中男性45名,女性45名,将志愿者随机分为3组,其中每组女性15名、男性15名。分别请第一组志愿者每日服用含实施例1护肤主剂1.0g的片剂或胶囊剂,分3~4次服用;
第二组志愿者每日服用含实施例1护肤主剂1.0g的片剂或胶囊剂,並用含实施例2护肤主剂1.0g的乳液剂制得护肤面膜,布敷于面部,每日1~2次,每次25~30分钟;
第三组志愿者每日服用维胺酯胶囊50mg,分3~4次服用,并每日用痤康王搽剂捈抹,分早中晚三次施用。
维胺酯胶囊和痤康王搽剂是目前临床治疗青春痘的主要药物。
然后,每间隔一段时间对各组志愿者进行回访,并按照无明显变化、有所好转、明显好转以及痊愈对各组志愿者青春痘恢复情况进行分类记录,并统计,结果如表1所示:
表1:
从以上实验可知,本发明实施例1和实施例2在治疗速度上和总有效率上都显著优于目前临床治疗青春痘的主要药物维胺酯胶囊和痤康王搽剂。尤其是实施例2中当α-硫辛酸在护肤主剂中的含量为40%时外用并以实施例1护肤主剂内服时,其修复皮肤以及清除自由基的功效更强,对青春痘的治疗效果更佳。
实施例3
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸30%、还原型谷胱甘肽8%、L-半胱氨酸9%、薰衣草提取物4%、丹参提取物11%、黄岑提取物9%、芦荟1.8%、根皮素0.3%、卵磷脂0.82%、维生素C 12%、维生素B2 6%、维生素B6 2%、维生素E 6%和叶酸0.08%。
随后,取100重量份上述护肤主剂,加甘油100重量份,加无菌水或果蔬汁500重量份,加入含ω-3脂肪酸的植物油10重量份,羧甲基纤维素钠0.25重量份,加入香精1份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂,随后浸泡纸膜,制得护肤面膜。
或取100重量份上述护肤主剂,加甘油50份,加无菌水或果蔬汁40份,加入含ω-3脂肪酸的植物油20重量份,羧甲基纤维素钠0.25重量份,加热至80℃搅打或以乳化机乳化成膏状,加入香精3份,制得霜剂。
实施例4
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸6%、还原型谷胱甘肽22%、L-半胱氨酸26%、薰衣草提取物2.0%、丹参提取物11%、黄岑提取物15%、芦荟粉3%、根皮素1%、阿魏酸2%、卵磷脂0.4%、维生素C 7%、维生素B2 2.14%、维生素B60.4%、维生素E 2%、叶酸0.06%。
随后,取100重量份上述护肤主剂,加入甘油1.5重量份、含丰富的ω-3脂肪酸的植物油2.5重量份、羧甲基纤维素钠0.4重量份和硬脂酸镁0.3重量份充分混合,然后进行制粒压片制作,制得片剂。
或将本护肤主剂放入加有脱氧剂包的自封塑料袋,外加铝箔袋脱气包装,以保护本护肤主剂不被空气氧化。
实施例5
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸30%、还原型谷胱甘肽13%、L-半胱氨酸18%、薰衣草提取物3%、丹参提取物7%、黄岑提取物7%、芦荟粉1.3%、阿魏酸0.6%、卵磷脂0.4%、维生素C 10%、维生素B2 2%、维生素B6 1%、维生素E6.5%、叶酸0.2%。
随后,取100重量份上述护肤主剂,加甘油100重量份,加无菌水或果蔬汁600重量份,羧甲基纤维素钠0.25重量份,加入香精1份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂。
或取100重量份上述护肤主剂,加甘油50份,加无菌水或果蔬汁40份,加入含ω-3脂肪酸的植物油20重量份,羧甲基纤维素钠0.3重量份,加热至75℃搅打或以乳化机乳化成膏状,加入香精3份,制得霜剂。
实施例6
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸40%、还原型谷胱甘肽4%、L-半胱氨酸12%、薰衣草提取物4%、丹参提取物9%、黄岑提取物8%、芦荟粉2%、根皮素0.5%、阿魏酸0.5%、卵磷脂1%、维生素C 8%、维生素B2 2%、维生素B6 2%、维生素E 6%、叶酸1%。
随后,取100重量份上述护肤主剂,加甘油100重量份,加果蔬汁600重量份,加入羧甲基纤维素钠0.25重量份,加入香精1份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂,随后浸泡纸膜,制得护肤面膜。
或取100重量份上述护肤主剂,加甘油50份,加无菌水或果蔬汁40份,加入含ω-3脂肪酸的植物油20重量份,羧甲基纤维素钠0.2重量份,加热至75℃搅打或以乳化机乳化成膏状,加入香精3份,制得霜剂。
实施例7
一种护肤主剂,按照重量百分数计,由以下组分制成:α-硫辛酸36%、还原型谷胱甘肽14%、L-半胱氨酸7%、薰衣草提取物6%、丹参提取物5%、黄岑提取物7%、芦荟粉3%、根皮素1%、阿魏酸2%、卵磷脂1%、维生素C 8%、维生素B24%、维生素B62%、维生素E 3%、叶酸1%。
随后,取100重量份上述护肤主剂,加甘油100重量份,加无菌水或果蔬汁600重量份,加入含ω-3脂肪酸的植物油10重量份,加入香精1份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂,随后浸泡纸膜,制得护肤面膜。
或取100重量份上述护肤主剂,加甘油50份,加无菌水或果蔬汁40份,加入含ω-3脂肪酸的植物油20重量份,羧甲基纤维素钠0.5重量份,加热至75℃搅打或以乳化机乳化成膏状,加入香精3份,制得霜剂。
效果例2
60名志愿者,均选自经医院诊断为色斑的患者,其中男性30名,女性30名,将志愿者随机分为2组,其中每组女性15名、男性15名,分别请第一组志愿者每日用含实施例7护肤主剂1g制得的护肤面膜,分早晚二次施用,每次25~30分钟,並每日服用含实施例4护肤主剂1g制得的胶囊剂,分3次服用;第二组志愿者每日服用氢醌乳膏捈抹,分早中晚三次施用,並每日服用康乃健祛黄褐斑片4片,分2次服用。
氢醌乳膏外用並以康乃健祛黄褐斑片内服是目前临床治疗色斑的主要方法。
然后,每间隔一段时间对各组志愿者进行回访,并按照无明显变化、有所好转、明显好转以及痊愈对各组志愿者色斑恢复情况进行分类记录,并统计结果如表2所示:
表2:
从以上实验可知,本发明实施例7护肤主剂外用并以实施例4护肤主剂内服时,在治疗速度上和总有效率上都显著优于目前临床治疗色斑的主要药物氢醌乳膏外用並以康乃健祛黄褐斑片内服。
尽管已用具体实施例来说明和描述了本发明,然而应意识到,在不背离本发明的精神和范围的情况下可以作出许多其它的更改和修改。因此,这意味着在所附权利要求中包括属于本发明范围内的所有这些变化和修改。
Claims (10)
1.一种护肤主剂,其特征在于,按照重量百分数计,所述护肤主剂主要由以下组分制成:α-硫辛酸7%~40%、还原型谷胱甘肽4%~22%、L-半胱氨酸7%~26%、薰衣草提取物3%~6%、丹参提取物5%~16%、黄岑提取物7%~15%、芦荟粉0%~3%、根皮素0%~2%、阿魏酸0%~2%、卵磷脂0.4%~1%、维生素C6%~12%、维生素E2%~7%、维生素B22%~6%、维生素B60.4%~2%、硫酸锌0%~2.5%和叶酸0.05%~1%。
2.如权利要求1所述的护肤主剂,其特征在于,按照重量百分数计,所述护肤主剂主要由以下组分制成:α-硫辛酸10%~30%、还原型谷胱甘肽6%~20%、L-半胱氨酸10%~20%、薰衣草提取物4%~5%、丹参提取物6%~15%、黄岑提取物8%~10%、芦荟粉1%~2%、根皮素1%~1.5%、阿魏酸1%~1.5%、卵磷脂0.6%~0.8%、维生素C8%~10%、维生素E3%~5%、维生素B23%~5%、维生素B60.6%~1.5%、硫酸锌0.5%~2%和叶酸0.06%~0.8%。
3.一种护肤主剂的制备方法,其特征在于,所述方法包括如下步骤:将权利要求1~2中任一项所述组分混合后,即得所述护肤主剂,这种护肤主剂可以直接用于护肤。
4.根据权利要求3所述的方法,其特征在于,所述护肤主剂可进一步加工成为片剂、胶囊剂、乳液剂、凝胶剂或霜剂中的一种。
5.根据权利要求3所述的方法,其特征在于,所述方法还进一步包括将权利要求1~2中任一项所述组分混合后,取100重量份组合物,加入甘油1~2重量份、富含ω-3脂肪酸的植物油1~5重量份、羧甲基纤维素钠0.2~0.5重量份和硬脂酸镁0.3~1.5重量份充分混合,随后进行制粒压片或灌装胶囊制作,制得片剂或胶囊剂。
6.根据权利要求3所述的方法,其特征在于,所述方法还进一步包括将权利要求1~2中任一项所述组分混合后,取100重量份组合物,加入甘油20~100重量份,加无菌水或果蔬汁200~600重量份,加入富含ω-3脂肪酸的植物油0~10重量份,羧甲基纤维素钠0.2~0.5重量份,加入香精1~3份,搅打均匀后,倾倒入乳化机乳化成奶状,制得乳液剂,随后还可将其浸泡纸膜,制得护肤面膜。
7.根据权利要求3所述的方法,其特征在于,所述方法还进一步包括将权利要求1~2中任一项所述组分混合后,取100重量份组合物,加甘油30~50份,加无菌水或果蔬汁20~60份,加富含ω-3脂肪酸的植物油20~40重量份,羧甲基纤维素钠0.2~0.5重量份,加热至75~80℃搅打或以乳化机乳化成膏状,加入香精1~3份,制得霜剂。
8.根据权利要5~7任一项所述的护肤主剂的制备方法,其特征在于,所述富含ω-3脂肪酸的植物油为奇亚子油、紫苏油、月见草油、胡麻子油中的一种或几种。
9.权利要求1~2中任一项所述护肤主剂在制备美白护肤药物中的应用。
10.根据权利要求9所述护肤主剂的应用,其特征在于,所述美白护肤是指防治青春痘、色斑和修复创伤色痕,其中,所述青春痘包括痤疮、粉刺、黑头和酒糟鼻;所述色斑包括雀斑、黄褐斑和老年斑。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610517463.4A CN106074206B (zh) | 2016-07-04 | 2016-07-04 | 一种护肤主剂、制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610517463.4A CN106074206B (zh) | 2016-07-04 | 2016-07-04 | 一种护肤主剂、制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106074206A true CN106074206A (zh) | 2016-11-09 |
CN106074206B CN106074206B (zh) | 2019-01-01 |
Family
ID=57211932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610517463.4A Expired - Fee Related CN106074206B (zh) | 2016-07-04 | 2016-07-04 | 一种护肤主剂、制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106074206B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107362117A (zh) * | 2017-09-04 | 2017-11-21 | 山东美貌化妆品股份有限公司 | 一种化妆品用复合添加剂及其制备方法 |
CN107375180A (zh) * | 2017-08-11 | 2017-11-24 | 北京斯利安药业有限公司 | 一种护肤品组合物、面膜及其制备方法 |
CN107375108A (zh) * | 2017-08-29 | 2017-11-24 | 北京军秀咨询有限公司 | 一种含薰衣草提取物的美白祛斑化妆品 |
CN107440996A (zh) * | 2017-09-04 | 2017-12-08 | 山东美貌化妆品股份有限公司 | 一种含有复合维生素的护肤品及其制备方法 |
CN107854328A (zh) * | 2017-10-16 | 2018-03-30 | 上海怡硕净化科技有限公司 | 一种pa4高效提亮护肤品 |
CN108379126A (zh) * | 2018-04-26 | 2018-08-10 | 广东岭南职业技术学院 | 一种鸸鹋油护肤膏及其制作方法 |
CN110638686A (zh) * | 2019-10-30 | 2020-01-03 | 华南理工大学 | 一种抑制色斑、抗皮肤光老化作用的护肤组合物及其应用 |
WO2021236958A1 (en) * | 2020-05-22 | 2021-11-25 | Auro Pharmaceuticals, Inc. | Compositions and methods of treatment with glutathione |
US11351262B2 (en) | 2011-06-16 | 2022-06-07 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1583030A (zh) * | 2004-06-02 | 2005-02-23 | 冯成铨 | 一种具有内服和外搽两用功能的保健霜及制备方法 |
CN102440386A (zh) * | 2010-10-15 | 2012-05-09 | 胥永贵 | 一种全复合人体抗氧化剂 |
-
2016
- 2016-07-04 CN CN201610517463.4A patent/CN106074206B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1583030A (zh) * | 2004-06-02 | 2005-02-23 | 冯成铨 | 一种具有内服和外搽两用功能的保健霜及制备方法 |
CN102440386A (zh) * | 2010-10-15 | 2012-05-09 | 胥永贵 | 一种全复合人体抗氧化剂 |
Non-Patent Citations (3)
Title |
---|
杨美花等: "L-半胱氨酸作为化妆品美白添加剂的作用机理", 《厦门大学学报(自然科学版)》 * |
王建新: "《化妆品植物原料大全》", 30 June 2012 * |
马振友: "《皮肤美容化妆品制剂手册》", 31 March 2004 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11351262B2 (en) | 2011-06-16 | 2022-06-07 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
US11602564B2 (en) | 2011-06-16 | 2023-03-14 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
CN107375180A (zh) * | 2017-08-11 | 2017-11-24 | 北京斯利安药业有限公司 | 一种护肤品组合物、面膜及其制备方法 |
CN107375180B (zh) * | 2017-08-11 | 2020-10-16 | 北京斯利安药业有限公司 | 一种护肤品组合物、面膜及其制备方法 |
CN107375108A (zh) * | 2017-08-29 | 2017-11-24 | 北京军秀咨询有限公司 | 一种含薰衣草提取物的美白祛斑化妆品 |
CN107362117A (zh) * | 2017-09-04 | 2017-11-21 | 山东美貌化妆品股份有限公司 | 一种化妆品用复合添加剂及其制备方法 |
CN107440996A (zh) * | 2017-09-04 | 2017-12-08 | 山东美貌化妆品股份有限公司 | 一种含有复合维生素的护肤品及其制备方法 |
CN107854328A (zh) * | 2017-10-16 | 2018-03-30 | 上海怡硕净化科技有限公司 | 一种pa4高效提亮护肤品 |
CN108379126A (zh) * | 2018-04-26 | 2018-08-10 | 广东岭南职业技术学院 | 一种鸸鹋油护肤膏及其制作方法 |
CN110638686A (zh) * | 2019-10-30 | 2020-01-03 | 华南理工大学 | 一种抑制色斑、抗皮肤光老化作用的护肤组合物及其应用 |
WO2021236958A1 (en) * | 2020-05-22 | 2021-11-25 | Auro Pharmaceuticals, Inc. | Compositions and methods of treatment with glutathione |
Also Published As
Publication number | Publication date |
---|---|
CN106074206B (zh) | 2019-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106074206A (zh) | 一种护肤主剂、制备方法及其应用 | |
CN102078283B (zh) | 一种中药美白祛斑营养乳膏 | |
CN102525870A (zh) | 中药美容面膜 | |
CN103571657A (zh) | 一种除痘的天然皂及其制备方法 | |
KR20010000396A (ko) | 미백 화장료 | |
CN104825347B (zh) | 一种医用生物美白袪斑敷料及其制备方法 | |
CN106511211B (zh) | 一种抗炎祛痘护肤乳液及其制备方法 | |
CN110368339A (zh) | 中药面膜组合物及其制备方法、使用方法 | |
CN114146014A (zh) | 一种复方烟酸薄荷酯植物多糖乳膏及其制备方法 | |
CN1289126C (zh) | 皮肤创面愈合剂 | |
CN106039022A (zh) | 一种亮肤美白中药组合物、亮肤美白中药制剂、亮肤美白面膜、制备方法 | |
CN105497537A (zh) | 一种具有美白嫩肤作用的药物组合物及其制备方法 | |
CN109010520A (zh) | 一种治疗暗疮的药膏及其制备方法 | |
KR102293585B1 (ko) | 왁스형 클렌저 | |
CN102641231B (zh) | 中药十二白润肤霜及其制备方法 | |
CN104306307A (zh) | 一种美白祛斑中药面膜 | |
CN108815112A (zh) | 美白祛斑中药面膜 | |
CN1647819A (zh) | 活性酶及组合物在胃病的防治和化妆品领域中的应用 | |
KR102329748B1 (ko) | 문제성 피부에 탁월한 왁스형 클렌저 | |
CN107375614A (zh) | 祛疤贴及其制备方法 | |
CN102018772A (zh) | 用于预防和治疗粉刺的中药蜜膏 | |
CN116270925A (zh) | 美白祛斑皂 | |
CN1100529C (zh) | 参甙抗衰去斑养颜膏 | |
CN104906022A (zh) | 祛斑纳米乳霜 | |
CN105147581A (zh) | 一种祛斑紧致美白霜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190101 Termination date: 20200704 |
|
CF01 | Termination of patent right due to non-payment of annual fee |